ResearchMoz

Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns

GBI Research
Published Date » 2014-03-13
No. Of Pages » 74
   
 GBI Research has released its pharma research: ‘Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns ’, which provides in-depth analysis of epilepsy market within the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of the market size for 2012, along with market forecasts to 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The value of the epilepsy market in the major developed markets amounted to an estimated $3.4 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 3.9% to reach $4.5...
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology
2.5 Pathophysiology
2.6 Co-morbidities/Complications
2.7 Diagnosis
2.8 Prognosis
2.9 Treatment Efficacy
2.10 Treatment Options
2.10.1 Ion Channel Modulators
2.10.2 GABA-ergic Facilitation
2.10.3 Excitatory Amino Acid Inhibitors
2.10.4 Synaptic Modulators
2.11 Non-pharmacological Management
2.11.1 Lobectomy and Lesionectomy
2.11.2 Ketogenic Diet and Modified Atkins Diet
2.11.3 Vagus Nerve Stimulation

3 Epilepsy Therapeutic Landscape
3.1 Overview
3.2 Lyrica (pregabalin)
3.3 Lamictal (lamotrigine)
3.4 Keppra (levetiracetam)
3.5 Zonegran (zonisamide)
3.6 Vimpat (lacosamide)
3.7 Aptiom/Zebinix (eslicarbazepine acetate)
3.8 Fycompa (perampanel)
3.9 Trobalt/Potiga (ezogabine/retigabine)
3.10 Banzel/Inovelon (rufinamide)
3.11 Comparative Efficacy and Safety of Marketed Products

4 Pipeline for Epilepsy Therapeutics
4.1 Overall Pipeline
4.2 Pipeline by Mechanism of Action
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Patient Enrolment and Clinical Trial Size
4.3.3 Clinical Trial Duration
4.4 Promising Pipeline Candidates
4.4.1 Brivaracetam – UCB
4.4.2 Ganaxolone – Marinus Pharmaceuticals

5 Epilepsy Therapeutics Market Forecast to 2019
5.1 Geographical Markets
5.1.1 Major Developed Markets
5.1.2 The US
5.1.3 Top Five EU Countries
5.1.4 Japan
5.1.5 Canada
5.2 Drivers and Barriers
5.2.1 Drivers
5.2.2 Barriers

6 Deals and Strategic Consolidations
6.1 Deals Analysis
6.2 Research and Development Co-development Agreements
6.3 Research and Development Licensing Agreements

7 Appendix
7.1 Abbreviations
7.2 References
7.3 References for Heat Maps
7.4 Pipeline Products by Phase
7.4.1 Discovery
7.4.2 Preclinical
7.4.3 IND-filed and Phase 0
7.4.4 Phase I
7.4.5 Phase II
7.4.6 Phase III
7.4.7 Pre-registration
7.5 Market Forecasting Data Tables to 2019
7.5.1 Major Developed Markets
7.5.2 US
7.5.3 UK
7.5.4 France
7.5.5 Germany
7.5.6 Italy
7.5.7 Spain
7.5.8 Japan
7.5.9 Canada
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer

List of Tables

Table 1: Epilepsy Therapeutics, Global, Types of Seizures, 2013
Table 2: Epilepsy Therapeutics, Heat Maps for Efficacy and Safety of Marketed Products, References
Table 3: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Discovery), 2013
Table 4: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Preclinical), 2013
Table 5: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013
Table 6: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase I), 2013
Table 7: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase II), 2013
Table 8: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase III), 2013
Table 9: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Pre-registration), 2013
Table 10: Epilepsy Therapeutics, Major Developed Markets, Market Forecast, 2012–2019
Table 11: Epilepsy Therapeutics, US, Market Forecast, 2012–2019
Table 12: Epilepsy Therapeutics, UK, Market Forecast, 2012–2019
Table 13: Epilepsy Therapeutics, France, Market Forecast, 2012–2019
Table 14: Epilepsy Therapeutics, Germany, Market Forecast, 2012–2019
Table 15: Epilepsy Therapeutics, Italy, Market Forecast, 2012–2019
Table 16: Epilepsy Therapeutics, Spain, Market Forecast, 2012–2019
Table 17: Epilepsy Therapeutics, Japan, Market Forecast, 2012–2019
Table 18: Epilepsy Therapeutics, Canada, Market Forecast, 2012–2019

List of Figures

Figure 1: Epilepsy Therapeutics, Epidemiology, Major Developed Markets, 2012
Figure 2: Epilepsy Therapeutics, Major Developed Markets, Approved Anti-epileptic Drugs, 2013
Figure 3: Epilepsy Therapeutics, Lyrica, Global, Revenue ($bn), 2013
Figure 4: Epilepsy Therapeutics, Lamictal, Global, Revenue ($m), 2009–2013
Figure 5: Epilepsy Therapeutics, Keppra, Global, Revenue ($bn), 2009–2013
Figure 6: Epilepsy Therapeutics, Zonegran, Global, Revenue ($m), 2009–2013
Figure 7: Epilepsy Therapeutics, Vimpat, Global, Revenue ($m), 2009–2013
Figure 8: Epilepsy Therapeutics, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013
Figure 9: Epilepsy Therapeutics, Global, Overall Pipeline Analysis, 2013
Figure 10: Epilepsy Therapeutics, Global, Pipeline Analysis, by Mechanism of Action, 2013
Figure 11: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Failure Rate, 2013
Figure 12: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Size, 2013
Figure 13: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Duration, 2013
Figure 14: Epilepsy Therapeutics, Major Developed Markets, Treatment Usage Pattern and Market Size, 2012–2019
Figure 15: Epilepsy Therapeutics, US, Treatment Usage Pattern, ACoT and Market Size, 2012–2019
Figure 16: Epilepsy Therapeutics, Top Five EU Countries, Treatment Patterns (‘000), 2012–2019
Figure 17: Epilepsy Therapeutics, Top Five EU Countries, Annual Cost of Treatment ($), 2012–2019
Figure 18: Epilepsy Therapeutics, Top Five EU Countries, Market Size ($m), 2012–2019
Figure 19: Epilepsy Therapeutics, Japan, Treatment Usage Pattern, ACoT and Market Size, 2012–2019
Figure 20: Epilepsy Therapeutics, Canada, Market Size, 2012–2019
Figure 21: Epilepsy Therapeutics, Deals by Region, Value and Year, 2006–2013
Figure 22: Epilepsy Therapeutics, Deals by Molecule Type and Mechanism of Action, 2006–2013
Figure 23: Epilepsy Therapeutics, Co-development Deals, Territory, 2006–2013
Figure 24: Epilepsy Therapeutics, Licensing Deals, by Territory, 2006–2013
Figure 25: GBI Research Market Forecasting Model

Upcoming Reports:

Vertebral Compression Fracture Devices Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Vertebral compression fracture (VCF), a spinal disorder is caused due to the compression of vertebrae because of trauma, osteoporosis, primary tumors or infections; resulting in spinal deformity, disability, and acute or chronic pain. Such fractures may be mild or severe in nature and most often occur in the thoracic and lumbar parts of the spinal cord. The non-surgical procedures for treating pain caused in VCF include bed rest, pain medication, back bracing, and physiotherapy. Modern VCF treatment options such as minimally invasive surgical procedures which involve injecting of cementing...
Mechano-Therapy Appliances, Massage Apparatus, And Psychological Aptitude-Testing Apparatus Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Mechano-therapy is an important type of therapy, which is done with the help of any mechanical apparatus and devices. The therapy is very useful in various kinds of medical conditions, such as, muscular pain, psychological cases, and other diseases. The term mechanotherapy is similar to massotherapy, literally means therapeutic massage.  The principle underlying the mechanotherapy is, the cells respond to mechanical load, and this cellular response leads to structure changes in pain area and initiate the process of healing. At present, a variety of mechanotherapy devices are...
Antioxidants Market - Global Industry Analysis, Market Size, Market Share, Growth And Forecast, 2012 - 2018
By - Transparency Market Research
Antioxidants are molecules that prevent other molecules from oxidizing. They act as free radicals in the human body and prevent the body from the chain of oxidation reaction by getting oxidized themselves or by eliminating radical intermediates. Different types of anti oxidants include vitamin E, Vitamin C, BHT, BHA and propyl gallate. Anti oxidants are used to safeguard the food from deterioration.  The global market for antioxidants is growing at a considerable rate with rapid growth in the Asia-Pacific and North America market. Europe represents the largest regional...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Hitachi Readies New Suite of Driving Systems
Oct 16, 2014  
Japan’s Hitachi Automotive Systems is all set to unveil a line of innovative autonomous driving technologies as the trend of high-tech and automotive electronics takes the industry by storm. The suite of technologies were unveiled in northern Japan last week and included features such as no-hands self-parking, vehicle stability control in electric automobiles, precrash braking, and...
Canadas Agreement on Waste-Water Treatment Boosts Indias PM Pet Clean Ganga Project
Oct 16, 2014  
In 2008, Canada and India adopted a bilateral science and technology collaboration agreement for Scientific and Technological Cooperation.  The pet Clean Ganga project led by the Indian Prime Minister Narendra Modi has received a confident boost with an agreement earlier on Wednesday. The agreement is all about cleaning up the most heavily used river in the world between Canada...
China Sends Experimental Ebola Drugs to Aid Workers, to Increase Supply if Found Effective
Oct 16, 2014  
An experimental Ebola drug has been sent to Africa for use by Chinese aid worker by a Chinese drug manufacturer. The company is plans to undertake clinical trials of the drug to combat the deadly Ebola outbreak in West Africa that has claimed more than 4000 lives so far. Several thousand doses of the drug JK-05, manufactured by Sihuan Pharmaceutical Holdings Group Ltd, have been...
Broccoli Based Chemical Gives Hope For Treating Autism
Oct 15, 2014  
According to the inferences derived from a small scale clinical trial, the chemical that is extracted from the sprouts of broccoli possess certain anti-cancerous properties. Moreover, this chemical may be able to even treat behavioral symptoms in those suffering from autism spectrum disorders. This research study was carried out by the scientists of Johns Hopkins University School of Medicine...
Toyota China to Recall Crown Sedans Due to Leaking Brake Fluid Issue
Oct 15, 2014  
Joining the global wave of automobile recalls, Toyota has announced its decision to recall 93,700 cars from the Chinese market to fix an issue regarding leaking brake fluid, Chinese quality watchdog has informed.  Tianjin FAW Toyota Motor Co, the Chinese subsidiary of Toyota Motor Corp., will recall the Crown model sedans manufactured by it between 1st December 2009 and 14th June 2012....